MedTrace Logo

Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure

NCT05816265 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-01

No results posted yet for this study

Summary

Patients with heart failure with reduced ejection fraction and iron deficiency will be randomized to either receive iron infusion or be in the control group. The study is looking at how iron replacement affects exercise capacity as measured by peak oxygen uptake.

Conditions

Interventions

DRUG

IV Iron Infusion Group

Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians

Sponsors & Collaborators

  • American Regent, Inc.

    collaborator INDUSTRY

  • Radha Gopalan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2026-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05816265 on ClinicalTrials.gov